Literature DB >> 8353228

Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome.

B Mishu1, M J Blaser.   

Abstract

Recent reports suggest that infection with Campylobacter jejuni, a common enteric pathogen, may cause Guillain-Barré syndrome (GBS) by triggering demyelination of peripheral nerves. GBS is preceded by an acute infectious illness (due to a variety of agents) in 50%-75% of cases; the onset of neurological symptoms is preceded by diarrhea in 10%-30% of cases. In the last decade, more than 20 published anecdotal reports and case series have described patients with C. jejuni infection documented 1-3 weeks before onset of GBS. Cultures of fecal samples obtained at the onset of neurological symptoms from patients with GBS have yielded C. jejuni in more than 25% of cases. A relatively rare serotype, Penner type O19, is overrepresented among isolates of C. jejuni from Japanese patients with GBS. Serological studies suggest that 20%-40% of patients with GBS have evidence of recent C. jejuni infection. In summary, infection with C. jejuni is a common antecedent to GBS and probably plays a role in initiating demyelination; although several pathogenic mechanisms are possible, none has been proven.

Entities:  

Mesh:

Year:  1993        PMID: 8353228     DOI: 10.1093/clinids/17.1.104

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

1.  Evaluation of the Alexon-trend ProSpecT Campylobacter microplate assay.

Authors:  R Tolcin; M M LaSalvia; B A Kirkley; E A Vetter; F R Cockerill; G W Procop
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 2.  Host-pathogen interactions in the immunopathogenesis of Lyme disease.

Authors:  L T Hu; M S Klempner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

Review 3.  Overview: Helicobacter pylori and extragastric disease.

Authors:  Hidekazu Suzuki; Barry James Marshall; Toshifumi Hibi
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

4.  Campylobacter jejuni disrupts protective Toll-like receptor 9 signaling in colonic epithelial cells and increases the severity of dextran sulfate sodium-induced colitis in mice.

Authors:  Jennifer R O'Hara; Troy D Feener; Carrie D Fischer; Andre G Buret
Journal:  Infect Immun       Date:  2012-02-06       Impact factor: 3.441

5.  Development and application of a new scheme for typing Campylobacter jejuni and Campylobacter coli by PCR-based restriction fragment length polymorphism analysis.

Authors:  Feng Shi; Yuen Yuen Chen; Trudy M Wassenaar; Walter H Woods; Peter J Coloe; Benjamin N Fry
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

6.  Development and characterization of recA mutants of Campylobacter jejuni for inclusion in attenuated vaccines.

Authors:  P Guerry; P M Pope; D H Burr; J Leifer; S W Joseph; A L Bourgeois
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

7.  Detection and identification of Campylobacter coli and Campylobacter jejuni by two-step polymerase chain reaction.

Authors:  G Comi; P Ferroni; L Cocolin; C Cantoni; M Manzano
Journal:  Mol Biotechnol       Date:  1995-06       Impact factor: 2.695

8.  Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides.

Authors:  J C Garcia-Monco; R J Seidman; J L Benach
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

9.  Campylobacter colonization and proliferation in the broiler chicken upon natural field challenge is not affected by the bird growth rate or breed.

Authors:  Fraser J Gormley; Richard A Bailey; Kellie A Watson; Jim McAdam; Santiago Avendaño; William A Stanley; Alfons N M Koerhuis
Journal:  Appl Environ Microbiol       Date:  2014-08-29       Impact factor: 4.792

10.  Analysis of HL and O serotypes of Campylobacter strains by the flagellin gene typing system.

Authors:  I Nachamkin; H Ung; C M Patton
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.